openPR Logo
Press release

Sufentanil - API Insight, 2018 | Aphios Corporation, Deltanoid Pharmaceuticals, Xeragenx LLC

05-03-2019 12:50 PM CET | Health & Medicine

Press release from: Sufentanil - Pharma Proff

Sufentanil - API Insight, 2018 | Aphios Corporation, Deltanoid

Sufentanil, sold under the brand names of Dsuvia and Sufenta, is basically a synthetic opioid analgesic drug, which is used for the medication of acute pain relief. It helps to offer properties of sedation and this makes it a good analgesic component of anesthetic regimen during a surgical process.

Download the sample report at: https://www.pharmaproff.com/request-sample/1167

It has greater potency than morphine and Fentanyl, often used in surgery and post-operative pain management for patients that are heavily opioid dependent or tolerant because of long term opiate use for chronic pain or illicit opiate use. In the present market, Sufentanil has proven to be the strongest opioid painkiller available.

Get the detailed analysis at: https://www.pharmaproff.com/report/sufentanil

In 2018, the Food and Drug Association had approved Dsuvia, a sublingual tablet form of the drug, that was developed in a collaboration between AcelRx Pharmaceuticals Inc. and the United States Department of Defense for use in battlefield settings where intravenous treatments may not be available. Some of the side-effects include heart rhythm irregularity, blood pressure changes and nausea/vomiting.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1167

This report provides details of the drug and the API manufacturers across the 7 major markets which includes U.S, EU5, and Japan. It includes the overview, mechanism, regulatory milestones, strategic developments, the historical and forecasted sales. The pipeline analysis of the drug by phase which would include the product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sufentanil - API Insight, 2018 | Aphios Corporation, Deltanoid Pharmaceuticals, Xeragenx LLC here

News-ID: 1726593 • Views:

More Releases for Sufenta

LTE Advanced Pro Market Set for Rapid Growth and Trend by 2021-2027 Covid-19 Ana …
LTE Advanced Pro market Research Report works on strategic research methodology, which greatly helps organizations to generate profits and get success in the global market. Market Research Analysis also depicts visionary innovations, future scenarios and market forecasts to drive important actions for leading business. It also focuses on marketing strategy which helps breaking a huge market into small segments to target customers. It also points out customer demands helps to